Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2388| Título : | Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders |
| Creador: | García de la Puente S |
| Nivel de acceso: | Open access |
| Palabras clave : | Colesterol - sangre - niño HDL-Colesterol - sangre - niño LDL-Colesterol -sangre - niño Estudios Cruzados - niño Relación Dosis-Respuesta a Droga - niño Método Doble Ciego - niño Hiperlipidemias - complicaciones - niño Hiperlipidemias - quimoterapia - niño Hipolipemiantes - efectos adversos - niño Hipolipemiantes - uso terapéutico - niño Enfermedades Renales - quimioterapia - niño Simvastatina - efectos adversos - niño Simvastatina - uso terapéutico - niño Resultado del Tratamiento Triglicéridos - sangre - niño Cholesterol - blood - child Cholesterol, HDL - blood - child Cholesterol, LDL - blood - child Cross-Over Studies - child Dose-Response Relationship, Drug - child Double-Blind Method - child Hyperlipidemias - complications - child Hyperlipidemias - drug therapy - child Hypolipidemic Agents - adverse effects - child Hypolipidemic Agents - therapeutic use - child Kidney Diseases - drug therapy - child Simvastatin - adverse effects - child Simvastatin - therapeutic use - child Treatment Outcome Triglycerides - blood - child Ensayo clínico, Hiperlipidemia, Simvastatina, Nefropatías, Niños Clinical trial . Hyperlipidemia . Simvastatin . Nephropathies. Children |
| Descripción : | Children with hyperlipidemia secondary to renal disease develop premature atherosclerosis and glomerulosclerosis. The aims of this pilot study were to find the dosage and short-term efficacy of simvastatin and potential adverse events in children with chronic kidney diseases. This was a random, double-blind, placebo-controlled, cross-over clinical trial performed on children with hyperlipidemia secondary to kidney disorders. After being placed on a diet for 3 months, patients were randomly placed in one of two balanced group blocks and treated with diet plus placebo or simvastatin at doses of 5 mg for children weighing 30 kg or less and 10 mg for children weighing over 30 kg, for 1 month, and then doubled for two more months. After this treatment, patients were placed on a diet for a 3-month washout period. During the last trial phase, patients previously treated with simvastatin were administered a placebo, and vice versa. A total of 25 patients with ages ranging from 4 years to 17 years were included in the study. A significant decrease in the levels of serum cholesterol (26.4%), low-density lipoprotein (LDL) (35.4%) and triglycerides (23.1%) was noted during the study, primarily during the simvastatin treatments, in which case cholesterol, LDL and triglycerides decreased by 23.3%, 33.7% and 21%, respectively. High-density lipoprotein (HDL) levels increased moderately (10.7%) during the study but without differences during simvastatin treatment. No differences were found across groups with respect to adverse events. In the short-term the combination of diet and simvastatin was effective in lowering hyperlipidemia in children with renal disorders. © IPNA 2009. |
| Colaborador(es) u otros Autores: | Arredondo-García JL Gutiérrez-Castrellón P Bojorquez-Ochoa A Maya ER Pérez-Martínez Mdel P |
| Fecha de publicación : | 2009 |
| Tipo de publicación: | Artículo |
| Formato: | |
| Identificador del Recurso : | 10.1007/s00467-009-1128-7 |
| Fuente: | Pediatric Nephrology 24(6):1205 - 1210 |
| URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2388 |
| Idioma: | eng |
| Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.